Alastair Compston

Compston's research focuses on the clinical science of human demyelinating disease including the discovery of genetic risk factors for multiple sclerosis and the introduction of alemtuzumab.^{[5][6][7] [8]}

Compston was formerly Professor of Neurology at the University of Wales, president of the European Neurological Society and the Association of British Neurologists, and editor of the journal Brain.^[9][10]

Compston's work has been recognised by prizes including the Charcot Award; the K-J Zülch Prize; the World Federation of Neurology Medal; the John Dystel Prize; the Richard and Mary Cave Award of the Multiple Sclerosis Society of Great Britain; the Hughlings Jackson Medal; the Galen Medal; and the Association of British Neurologists Medal.^[9]

Compston was elected a Fellow of the Royal Society (FRS) in 2016^[9] and appointed Commander of the Order of the British Empire (CBE) in the 2016 New Year Honours for services to multiple-sclerosis treatment.^[11] He was elected a fellow of the Academy of Medical Sciences,^[when?] and a foreign member of the National Academy of Sciences of Germany^[when?] and the National Academy of Medicine of the United States.^[when?]